Kathy Miller

28PUBLICATIONS
210CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Epidemiological modellingMolecular targetsPredictive and prognostic markersLiquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (28)

|Aug 20, 2026
Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR.

|May 30, 2026
Impact of patient-reported taxane-induced peripheral neuropathy on dose reductions or worsening quality of life in Black women with breast cancer: Analysis from ECOG-ACRIN EAZ171.

|Apr 14, 2026
A phase 1 study of ASTX727 plus talazoparib in patients with triple-negative or hormone resistant/HER2-negative metastatic breast cancer.

Kathy D Miller, Alexandra Thomas, Sandra Althouse

|Feb 25, 2026
A Co-Design Study Developing an Early Prototype Intervention to Support Oral Anticancer Medication Use in Breast Cancer.

Yejin Seo, Karen Suchanek Hudmon, Kellie Jones Weddle

|Aug 25, 2025
Circulating Tumor Cell Dynamics after CDK4/6 Inhibitor for Hormone Receptor-Positive Metastatic Breast Cancer: A Biomarker Analysis from the PACE Phase II Study.

Lorenzo Gerratana, Carolina Reduzzi, Yue Ren

|Apr 29, 2025
A Phase II Randomized Study of Paclitaxel Alone or Combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor-Positive Breast Cancer: The BRACELET-01/PrE0113 Study.

Amy S Clark, Fengmin Zhao, Paula Klein

Pageof 5

Frequent Collaborators

5 joint publications

Antonio C Wolff

5 joint publications

Angela DeMichele

5 joint publications

Bryan P Schneider

5 joint publications

Tarah J Ballinger